Pages that link to "Q34230234"

The following pages link to Generation of mutated variants of the human form of the MHC class I-related receptor, FcRn, with increased affinity for mouse immunoglobulin G. (Q34230234):

Displaying 35 items.

• Neonatal Fc receptor mediates internalization of Fc in transfected human endothelial cells (Q24651849) (← links)
• Fc-fusion proteins and FcRn: structural insights for longer-lasting and more effective therapeutics (Q26822421) (← links)
• Targeting FcRn for the modulation of antibody dynamics (Q28080589) (← links)
• Neonatal Fc receptor and IgG-based therapeutics (Q28252134) (← links)
• The neonatal Fc receptor, FcRn, as a target for drug delivery and therapy (Q28257521) (← links)
• The effect of pH dependence of antibody-antigen interactions on subcellular trafficking dynamics (Q30566003) (← links)
• Exocytosis of IgG as mediated by the receptor, FcRn: an analysis at the single-molecule level (Q30815399) (← links)
• Tailoring the pharmacokinetics and positron emission tomography imaging properties of anti-carcinoembryonic antigen single-chain Fv-Fc antibody fragments. (Q34134336) (← links)
• Neonatal Fc receptor: from immunity to therapeutics (Q34268801) (← links)
• Clinical Ramifications of the MHC Family Fc Receptor FcRn (Q34754673) (← links)
• Robust expression of the human neonatal Fc receptor in a truncated soluble form and as a full-length membrane-bound protein in fusion with eGFP (Q35049552) (← links)
• Divergent activities of an engineered antibody in murine and human systems have implications for therapeutic antibodies (Q35214746) (← links)
• Subcutaneous bioavailability of therapeutic antibodies as a function of FcRn binding affinity in mice (Q35918870) (← links)
• Improved tumor imaging and therapy via i.v. IgG-mediated time-sequential modulation of neonatal Fc receptor (Q35945192) (← links)
• CD47 is an adverse prognostic factor and a therapeutic target in gastric cancer (Q36051761) (← links)
• Antibody constructs in cancer therapy: protein engineering strategies to improve exposure in solid tumors (Q36677197) (← links)
• Germline deletion of β2 microglobulin or CD1d reduces anti-phospholipid antibody, but increases autoantibodies against non-phospholipid antigens in the NZB/W F1 model of lupus (Q36903316) (← links)
• Mechanism of increased clearance of glycated albumin by proximal tubule cells (Q36957107) (← links)
• N-Glycan Moieties in Neonatal Fc Receptor Determine Steady-state Membrane Distribution and Directional Transport of IgG. (Q37136734) (← links)
• Targeting the neonatal fc receptor for antigen delivery using engineered fc fragments. (Q37334251) (← links)
• Chapter 4: Multitasking by exploitation of intracellular transport functions the many faces of FcRn. (Q37597698) (← links)
• The effect of the neonatal Fc receptor on human IgG biodistribution in mice (Q38718124) (← links)
• Impact of altered endogenous IgG on unspecific mAb clearance (Q38821722) (← links)
• Cross-species binding analyses of mouse and human neonatal Fc receptor show dramatic differences in immunoglobulin G and albumin binding (Q39540318) (← links)
• Scale-up of a physiologically-based pharmacokinetic model to predict the disposition of monoclonal antibodies in monkeys (Q40545249) (← links)
• Characterization of the interactions of rabbit neonatal Fc receptor (FcRn) with rabbit and human IgG isotypes (Q42366290) (← links)
• Towards a platform PBPK model to characterize the plasma and tissue disposition of monoclonal antibodies in preclinical species and human (Q44019028) (← links)
• A generic whole body physiologically based pharmacokinetic model for therapeutic proteins in PK-Sim. (Q46242399) (← links)
• The antibody drug absorption following subcutaneous or intramuscular administration and its mathematical description by coupling physiologically based absorption process with the conventional compartment pharmacokinetic model (Q51253905) (← links)
• Engineering the Fc region of immunoglobulin G to modulate in vivo antibody levels (Q51348965) (← links)
• Changes in complementarity-determining regions significantly alter IgG binding to the neonatal Fc receptor (FcRn) and pharmacokinetics. (Q54979517) (← links)
• Translational PBPK Modeling of the Protein Therapeutic and CD95L Inhibitor Asunercept to Develop Dose Recommendations for Its First Use in Pediatric Glioblastoma Patients. (Q64927868) (← links)
• Physiologically-based pharmacokinetic (PBPK) model to predict IgG tissue kinetics in wild-type and FcRn-knockout mice (Q80629501) (← links)
• Analysis of the expression of immunoglobulins throughout lactation suggests two periods of immune transfer in the tammar wallaby (Macropus eugenii) (Q80865146) (← links)
• Understanding the Monoclonal Antibody Disposition after Subcutaneous Administration using a Minimal Physiologically based Pharmacokinetic Model (Q90242807) (← links)